Yubo International Biotech Limited filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the period ended September 30, 2026.

Key Highlights

  • Share count as of November 10, 2026: 170,416,343 shares of Class A Common Stock ($0.001 par value) and 4,447 shares of Class B Common Stock ($0.001 par value) were outstanding.
  • VIE structure disclosed: The company operates in China through contractual arrangements with Yubo International Biotech (Beijing) Limited, a variable interest entity; the company holds no equity interest in Yubo Beijing or its subsidiaries.
  • Investor exposure: According to the filing, investors in Class A common stock "currently do not hold, and may never hold, any equity interest, directly or indirectly, in Yubo Beijing or any of its subsidiaries."
  • Regulatory risk flagged: The filing states that if PRC authorities disallow the contractual arrangements, "the value of our Class A common stock...could significantly decline or become worthless."
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company; it is not an emerging growth company.
  • No securities registered under Section 12(b): The filing states "None" for securities registered pursuant to Section 12(b) of the Act.

Yubo International Biotech's VIE Structure and China Operations for Q3 2026

Yubo International Biotech Limited, a New York corporation, filed its quarterly report for the period ended September 30, 2026. The company describes itself as a U.S. holding company operating primarily through Platinum International Biotech Co., Ltd., a Cayman Islands holding company. Platinum in turn operates in China through subsidiaries and contractual arrangements with its VIE, Yubo International Biotech (Beijing) Limited. The filing notes that "none of our Company, Platinum, or Platinum HK, each as a holding company, conducts any day-to-day business operations in China."

The filing discloses that Yubo Beijing and its subsidiaries - including Phoenix Club Bio-Medical Technology (Chengdu) Co., Ltd., Yubo Jingzhi Biotechnology (Chengdu) Co., Ltd., and EpiAis Biomedical Engineering Co., Ltd. - conduct day-to-day business operations in China. The company stated that its "contractual arrangements with Yubo Beijing have not been tested in a court of law," and that if the PRC government finds these arrangements non-compliant with restrictions on direct foreign investment, "we could be subject to severe penalties or be forced to relinquish our interests in Yubo Beijing or forfeit our rights under the contractual arrangements."

The filing also includes forward-looking statements subject to the company's cautionary language, addressing areas such as stem cell research and development activities, the need for additional funding, regulatory approvals, and intellectual property protection. The company cautions that actual results could differ materially from those anticipated in such statements.

What Was Disclosed

Yubo International Biotech filed its Form 10-Q for the quarter ended September 30, 2026, disclosing share counts, its VIE-based operating structure in China, associated regulatory risks, and forward-looking statements covering R&D, funding, and regulatory matters.